These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 31730023)

  • 1. Nonsteroidal sulfamate derivatives as new therapeutic approaches for Neurofibromatosis 2 (NF2).
    Shen YC; Arellano-Garcia C; Menjivar RE; Jewett EM; Dohle W; Karchugina S; Chernoff J; Potter BVL; Barald KF
    BMC Pharmacol Toxicol; 2019 Nov; 20(1):67. PubMed ID: 31730023
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeted NF1 cancer therapeutics with multiple modes of action: small molecule hormone-like agents resembling the natural anticancer metabolite, 2-methoxyoestradiol.
    Shen YC; Upadhyayula R; Cevallos S; Messick RJ; Hsia T; Leese MP; Jewett DM; Ferrer-Torres D; Roth TM; Dohle W; Potter BV; Barald KF
    Br J Cancer; 2015 Oct; 113(8):1158-67. PubMed ID: 26461061
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumorigenesis in neurofibromatosis: new insights and potential therapies.
    Reed N; Gutmann DH
    Trends Mol Med; 2001 Apr; 7(4):157-62. PubMed ID: 11286939
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neurofibromatosis and associated tumour suppressor genes.
    Zwarthoff EC
    Pathol Res Pract; 1996 Jul; 192(7):647-57. PubMed ID: 8880865
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Advances in the treatment of neurofibromatosis-associated tumours.
    Lin AL; Gutmann DH
    Nat Rev Clin Oncol; 2013 Nov; 10(11):616-24. PubMed ID: 23939548
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CAPE (caffeic acid phenethyl ester)-based propolis extract (Bio 30) suppresses the growth of human neurofibromatosis (NF) tumor xenografts in mice.
    Demestre M; Messerli SM; Celli N; Shahhossini M; Kluwe L; Mautner V; Maruta H
    Phytother Res; 2009 Feb; 23(2):226-30. PubMed ID: 18726924
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Optimizing biologically targeted clinical trials for neurofibromatosis.
    Gutmann DH; Blakeley JO; Korf BR; Packer RJ
    Expert Opin Investig Drugs; 2013 Apr; 22(4):443-62. PubMed ID: 23425047
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A clue to the therapy of neurofibromatosis type 2: NF2/merlin is a PAK1 inhibitor.
    Hirokawa Y; Tikoo A; Huynh J; Utermark T; Hanemann CO; Giovannini M; Xiao GH; Testa JR; Wood J; Maruta H
    Cancer J; 2004; 10(1):20-6. PubMed ID: 15000491
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The genetic and molecular pathogenesis of NF1 and NF2.
    Yohay KH
    Semin Pediatr Neurol; 2006 Mar; 13(1):21-6. PubMed ID: 16818172
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combining curcumin (diferuloylmethane) and heat shock protein inhibition for neurofibromatosis 2 treatment: analysis of response and resistance pathways.
    Angelo LS; Wu JY; Meng F; Sun M; Kopetz S; McCutcheon IE; Slopis JM; Kurzrock R
    Mol Cancer Ther; 2011 Nov; 10(11):2094-103. PubMed ID: 21903608
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The neurofibromatoses: when less is more.
    Gutmann DH
    Hum Mol Genet; 2001 Apr; 10(7):747-55. PubMed ID: 11257108
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cell Fate following Irradiation of MDA-MB-231 and MCF-7 Breast Cancer Cells Pre-Exposed to the Tetrahydroisoquinoline Sulfamate Microtubule Disruptor STX3451.
    Hargrave SD; Joubert AM; Potter BVL; Dohle W; Marais S; Mercier AE
    Molecules; 2022 Jun; 27(12):. PubMed ID: 35744942
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The motor protein kinesin-1 links neurofibromin and merlin in a common cellular pathway of neurofibromatosis.
    Hakimi MA; Speicher DW; Shiekhattar R
    J Biol Chem; 2002 Oct; 277(40):36909-12. PubMed ID: 12191989
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Ras inhibitor farnesylthiosalicylic acid as a potential therapy for neurofibromatosis type 1.
    Barkan B; Starinsky S; Friedman E; Stein R; Kloog Y
    Clin Cancer Res; 2006 Sep; 12(18):5533-42. PubMed ID: 17000690
    [TBL] [Abstract][Full Text] [Related]  

  • 15. NF2: the wizardry of merlin.
    Xiao GH; Chernoff J; Testa JR
    Genes Chromosomes Cancer; 2003 Dec; 38(4):389-99. PubMed ID: 14566860
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical and molecular characterization of neurofibromatosis in southern Brazil.
    Rosset C; Vairo F; Cristina Bandeira I; Fonini M; Netto CBO; Ashton-Prolla P
    Expert Rev Mol Diagn; 2018 Jun; 18(6):577-586. PubMed ID: 29685074
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Progress toward the isolation and characterization of the genes causing neurofibromatosis.
    Menon AG; Gusella JF; Seizinger BR
    Brain Pathol; 1990 Sep; 1(1):33-40. PubMed ID: 1669691
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New insights into the neurofibromatoses.
    Gutmann DH
    Curr Opin Neurol; 1994 Apr; 7(2):166-71. PubMed ID: 8019663
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Functional analysis of neurofibromatosis 2 (NF2) missense mutations.
    Gutmann DH; Hirbe AC; Haipek CA
    Hum Mol Genet; 2001 Jul; 10(14):1519-29. PubMed ID: 11448944
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Seizures in neurofibromatosis. What is the risk?].
    Drouet A
    Rev Neurol (Paris); 2011 Dec; 167(12):886-96. PubMed ID: 22041820
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.